News & Updates

Show Multimedia Only

Sleep apnoea ups CVD risk in patients with cancer

06 Sep 2026 by

Obstructive sleep apnoea (OSA) contributes to an increased risk of cardiovascular disease (CVD) events for patients with cancer, and this risk increase persists regardless of obesity status and is more pronounced in women, according to a retrospective study.

Sleep apnoea ups CVD risk in patients with cancer

06 Sep 2026

Original New Drug Application Approvals by US FDA (1-15 August 2026)

03 Sep 2026

New drug applications approved by US FDA as of 1-15 August 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 August 2026)

03 Sep 2026

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

New drug applications approved by US FDA as of 16-31 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

Intensified triplet regimens may improve PFS in mHSPC

01 Sep 2026 by

First-line combination treatment with docetaxel plus androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) or poly(ADP-ribose) polymerase inhibitor (PARPi) plus ARPI plus ADT results in clinically relevant but not statistically significant improvements in progression-free survival (PFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), a study has found.

Intensified triplet regimens may improve PFS in mHSPC

01 Sep 2026

Drug interactions not uncommon in breast cancer patients on chemo

27 Aug 2026 by

Potential drug-drug interactions (DDIs) exist in breast cancer patients undergoing cyclin-dependent kinase (CDK) 4/6 inhibitors chemotherapy, suggests a study.

Drug interactions not uncommon in breast cancer patients on chemo

27 Aug 2026

Ribociclib improves survival in advanced breast cancer

26 Aug 2026

Ribociclib combined with letrozole or fulvestrant demonstrates robust progression-free (PFS) and overall survival (OS), with modest objective response rates in heavily pretreated patients with advanced breast cancer, according to a real-world study.

Ribociclib improves survival in advanced breast cancer

26 Aug 2026

Biomarkers may be the key to unlocking the full potential of ADCs.

26 Aug 2026 by

Antibody-drug conjugates (ADCs) are an important therapeutic option in advanced non-small cell lung cancer (NSCLC), but the right patient selection remains a major challenge. Professor David P. Carbone, Director, Thoracic Oncology Center, Ohio State University Medical Center, Ohio, US, discussed the evolving role of biomarkers in guiding therapy with ADC.

Biomarkers may be the key to unlocking the full potential of ADCs.

26 Aug 2026

ADCs: An emerging class of targeted cancer therapies

26 Aug 2026 by

Antibody-drug conjugates (ADCs) are revolutionising the treatment of cancer by combining the specificity of targeted therapy with the potency of cytotoxic chemotherapy, said Dr David Lee, a consultant clinical oncologist.

ADCs: An emerging class of targeted cancer therapies

26 Aug 2026

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

25 Aug 2026 by

A phase II study of patients with heavily pretreated B-cell non-Hodgkin lymphoma (NHL) reports decade-long remissions in approximately one-third of patients with large B-cell lymphomas (LBCL) and in nearly half of patients with follicular lymphoma (FL), following a single infusion of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, tisagenlecleucel.

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

25 Aug 2026

Juvenile-onset mycosis fungoides progression not common, survival high: study

22 Aug 2026

Juvenile-onset mycosis fungoides (jMF) is usually diagnosed during its early stage and has an excellent prognosis, with overall survival (OS) of 99 percent at 5 years and 98 percent at 10 years, reveals a study.

Juvenile-onset mycosis fungoides progression not common, survival high: study

22 Aug 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Sleep apnoea ups CVD risk in patients with cancer

Sleep apnoea ups CVD risk in patients with cancer

Original New Drug Application Approvals by US FDA (1-15 August 2026)

Original New Drug Application Approvals by US FDA (1-15 August 2026)

Original New Drug Application Approvals by US FDA (16-31 July 2026)

Original New Drug Application Approvals by US FDA (16-31 July 2026)

Intensified triplet regimens may improve PFS in mHSPC

Intensified triplet regimens may improve PFS in mHSPC

Drug interactions not uncommon in breast cancer patients on chemo

Drug interactions not uncommon in breast cancer patients on chemo

Ribociclib improves survival in advanced breast cancer

Ribociclib improves survival in advanced breast cancer

Biomarkers may be the key to unlocking the full potential of ADCs.

Biomarkers may be the key to unlocking the full potential of ADCs.

ADCs: An emerging class of targeted cancer therapies

ADCs: An emerging class of targeted cancer therapies

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

10-year OS rates reach 32–47 percent in R/R B-cell NHL after CAR T-cell therapy

Juvenile-onset mycosis fungoides progression not common, survival high: study

Juvenile-onset mycosis fungoides progression not common, survival high: study